To address the concerns of the immunosuppressed transplant community to the COVID-19 pandemic, CareDx has launched RemoTraC, a solution enabling remote home-based monitoring of transplant patients. RemoTraC is a remote home-based blood draw product that uses mobile phlebotomy for AlloSure and AlloMap surveillance tests, as well as for other standard monitoring tests.
RemoTraC will be offered to all patients who want their transplant monitoring lab tests to be drawn at home by trained mobile phlebotomists, CareDx said. The company has built a national network of blood draw options for the transplant community. Patients can register through the web.